[18F]5-氟氨基辛二酸与(4S)-4-(3-[18F]氟丙基)-L-谷氨酸作为靶向系统xC-的放射性药物的对比评价
该研究在体外细胞和荷瘤小鼠中直接对比了靶向系统xC-的两种18F标记氨基酸放射性药物[18F]FASu与[18F]FSPG的摄取特异性和显像能力。体外实验显示[18F]FSPG在所有受试细胞系中摄取均高于[18F]FASu;体内PET/CT中两者均可对胶质母细胞瘤U-87和非小细胞肺癌A549移植瘤清晰显像,但U-87瘤中[18F]FSPG摄取显著高于[18F]FASu。
要点
- 体外所有受试细胞系中[18F]FSPG摄取均高于[18F]FASu。
- U-87移植瘤中[18F]FSPG摄取显著高于[18F]FASu(P=0.0321)。
- A549移植瘤中两者摄取差异无统计学意义(P=0.7786)。
核心结论
- [18F]FSPG在体外所有受试细胞系中摄取均高于[18F]FASu,但两者间仍存在残余摄取差异,提示受试细胞系中存在替代转运体活性;体内研究显示[18F]FASu和[18F]FSPG均可对胶质母细胞瘤U-87和非小细胞肺癌A549移植瘤显像。
研究设计与样本
- 研究按既往发表方法合成两种示踪剂,用前列腺癌PC-3、胶质母细胞瘤U-87、结直肠癌HT-29、卵巢癌SKOV3、乳腺癌MDA-MB-231和肺癌A549细胞系进行体外摄取特异性实验,并在荷U-87或A549移植瘤的免疫缺陷小鼠中进行PET/CT显像和生物分布研究。
主要发现
- 体外细胞摄取实验显示两种示踪剂在癌细胞中呈时间依赖性蓄积,[18F]FASu摄取可被系统xC-抑制剂磺胺沙拉嗪和玫瑰红阻断,但不被系统L抑制剂2-氨基双环-(2,2,1)-庚烷-2-羧酸、系统xC-抑制剂L-反式-吡咯烷-2,4-二羧酸或L-丝氨酸阻断。加入过量L-反式-吡咯烷-2,4-二羧酸后,[18F]FSPG摄取在3个受试细胞系中的2个显著下降。体内PET/CT中两种示踪剂在荷U-87和A549瘤小鼠中均产生良好对比度图像。注射后1小时A549瘤摄取为[18F]FASu 5.0±0.8 %ID/g(n≥5)vs [18F]FSPG 6.3±1.3 %ID/g(n≥6,P=0.7786);U-87移植瘤摄取为[18F]FASu 6.1±2.4 %ID/g(n≥4)vs [18F]FSPG 11.2±4.1 %ID/g(n≥4,P=0.0321)。
关键数值与推荐
- A549移植瘤注射后1小时摄取:[18F]FASu 5.0±0.8 %ID/g(n≥5)vs [18F]FSPG 6.3±1.3 %ID/g(n≥6,P=0.7786)。
- U-87移植瘤注射后1小时摄取:[18F]FASu 6.1±2.4 %ID/g(n≥4)vs [18F]FSPG 11.2±4.1 %ID/g(n≥4,P=0.0321)。
局限性
- 作者指出[18F]FSPG与[18F]FASu之间仍存在残余摄取差异,提示受试细胞系中存在替代转运体活性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
System [Formula: see text] is an appealing biomarker for targeting oxidative stress with oncologic PET imaging and can serve as an alternative PET biomarker to other metabolic indicators. In this paper, we report a direct comparison of 2 18F-labeled amino acid radiopharmaceuticals targeting system [Formula: see text], [18F]5-fluoroaminosuberic acid ([18F]FASu) and (4S)-4-(3-[18F]fluoropropyl)-l-glutamate ([18F]FSPG), in terms of their uptake specificity and ability to image glioma and lung cancer xenografts in vivo. Methods: Both tracers were synthesized according to previously published procedures. In vitro uptake specificity assays were conducted using prostate (PC-3), glioblastoma (U-87), colorectal (HT-29), ovarian (SKOV3), breast (MDA-MB-231), and lung cancer (A549) cell lines. PET/CT imaging and biodistribution studies were conducted in immunocompromised mice bearing U-87 or A549 xenografts. Results: In vitro cell uptake assays showed that the tracers accumulated in cancer cells in a time-dependent manner and that the uptake of [18F]FASu was blocked by the system [Formula: see text] inhibitor sulfasalazine and rose bengal, but not by system L inhibitor 2-aminobicyclo-(2,2,1)-heptane-2-carboxylic acid, system [Formula: see text] inhibitor L-trans-pyrrolidine-2,4-dicarboxylic acid, or l-serine, which is a substrate for transporter systems A, ACS, B0, and B0,+ Conversely, [18F]FSPG uptake decreased significantly in the presence of an excess of L-trans-pyrrolidine-2,4-dicarboxylic acid in 2 of 3 tested cell lines, indicating some reliance on system [Formula: see text] in these cells. In an in vivo setting, [18F]FASu and [18F]FSPG generated good-contrast PET images in U-87 and A549 tumor-bearing mice. Tracer accumulation in A549 tumors was 5.0 ± 0.8 percentage injected dose (%ID)/g ([18F]FASu, n ≥ 5) and 6.3 ± 1.3 %ID/g ([18F]FSPG, n ≥ 6, P = 0.7786), whereas U-87 xenografts demonstrated uptake of 6.1 ± 2.4 %ID/g ([18F]FASu, n ≥ 4) and 11.2 ± 4.1 %ID/g ([18F]FSPG, n ≥ 4, P = 0.0321) at 1 h after injection. Conclusion: [18F]FSPG had greater in vitro uptake than [18F]FASu in all cell lines tested; however, our results indicate that residual uptake differences exist between [18F]FSPG and [18F]FASu, suggesting alternative transporter activity in the cell lines tested. In vivo studies demonstrated the ability of both [18F]FASu and [18F]FSPG to image glioblastoma (U-87) and non-small cell lung cancer (A549) xenografts.
引用
- Colovic M, Yang H, Southcott L, et al. Comparative Evaluation of [18F]5-Fluoroaminosuberic Acid and (4S)-4-3-[18F]fluoropropyl)-l-Glutamate as System xC--Targeting Radiopharmaceuticals. J Nucl Med. 2023. PMID: 37116917. doi:10.2967/jnumed.122.265254
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。